Source-grounded facts extracted from uniQure N.V.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
uniQure N.V. reported financial results for first quarter of 2026.
“uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.”
uniQure N.V. incurred term loan of maximum aggregate amount of $175 million with Hercules Capital, Inc. at greater of (i) 9.45% and (ii) the sum of the prime rate and 2.45% maturing October 1, 2030.
“On September 22, 2025 (the “ Closing Date ”), uniQure N.V. (the “ Company ”) and certain of its affiliates entered into Amendment No. 3 to the Third Amended and Restated Loan and Security Agreement (the “ Amendment ”) with Hercules Capital, Inc. (“ Hercules ”), which amended certain terms of the Third Amended and Restated Loan and Security Agreement, dated December 15, 2021, by and among the Company, certain subsidiaries of the Company, and Hercules, as amended by that certain Amendment No. 1 to Third Amended and Restated Loan and Security Agreement, dated as of May 12, 2023 and Consent and Amendment No. 2 to Third Amended and Restated Loan and Security Agreement, dated as of June 28, 2024 (the “ Existing Loan Agreement ,” and the Existing Loan Agreement as amended by the Amendment, the “ Loan Agreement ”). Pursuant to the Amendment, Hercules agreed to make additional term loans in the maximum aggregate amount of $175 million (the “ 2025 Term Loan ”) to refinance the existing term loan”
Pierre Caloz was terminated as Chief Operating Officer at uniQure N.V..
“In connection with the closing of the Lexington Transaction, on July 22, 2024, the Company notified Pierre Caloz, the Company’s Chief Operating Officer, that his employment was being terminated consistent with the terms of the employment agreement by and between uniQure biopharma B.V. and Mr. Caloz, dated May 17, 2021.”
uniQure N.V. reported the quarter ended March 31, 2024 results: revenue $8.5 million.
“Revenue for the three months ended March 31, 2024 was $8.5 million, compared to $5.3 million in the same period in 2023.”
Paula Soteropoulos departed as Non-executive director at uniQure N.V..
“On April 9, 2024, Paula Soteropoulos notified the board of directors (the “ Board ”) of uniQure N.V. (the “ Company ”) that she will not stand for re-election as a non-executive director when her current term expires at Company’s 2024 annual meeting of shareholders.”
uniQure N.V. reported fourth quarter and full year 2023 results: revenue $15.8 million.
“Company expects cash, cash equivalents and investment securities will fund operations into the second quarter of 2027. Revenues: Revenue for the year ended December 31, 2023 was $15.8 million, compared to $106.5 million in the same period in 2022. Revenues in 2022 included $100.0 million of license revenue related to the U.S. first sale milestone payment of HEMGENIX ®”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.